Publication Name	World Journal of Pharmacology
Manuscript ID	12108
Country	Egypt

Received	2014-06-23 09:27
Peer-Review Started	2014-06-23 13:39
To Make the First Decision	2014-07-10 17:26
Return for Revision	2014-07-17 22:40
Revised	2015-01-26 00:00
Second Decision	2015-02-04 11:49
Accepted by Journal Editor-in-Chief	2015-02-05 18:13
Accepted by Company Editor-in-Chief	2015-02-11 16:04
Articles in Press	2015-02-11 16:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-02-27 15:41
Publish the Manuscript Online	2015-03-12 19:39

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Review
Article Title	Drug therapy for Parkinson’s disease: An update
Manuscript Source	Invited Manuscript
All Author List	Omar ME Abdel-Salam
Funding Agency and Grant Number
Corresponding Author	Omar ME Abdel-Salam, MD, PhD, Department of Toxicology and Narcotics, Medical Division, National Research Centre, Tahrir Street, Cairo 12311, Egypt. omasalam@hotmail.com
Key Words	Parkinson disease; Levodopa; Dopaminergic drugs; Neuroprotective agents; Non-dopaminergic drugs; Mitochondrial enhancers
Core Tip	Parkinson’s disease (PD) is a neurodegenerative disorder for which currently there is no cure. The advent of many therapies such as levodopa (L-dopa), dopamine-receptor-agonists, monoamine oxidase type B inhibitors, and catechol-O-methyltransferase inhibitors helped much to ease the life and to improve health-related quality of life of PD patients. Among these drugs, L-dopa remains the most effective agent for treatment of motor symptoms in PD. These agents provide symptomatic relief for motor symptoms but there is no evidence that these could alter the natural course of the disease and prevent the progressive dopaminergic neuronal loss. There is, however, encouraging data that suggest a benefit from iron chelation therapy with deferiprone and from the use of antioxidants or mitochondrial function enhancers in preventing or delaying the progression of PD.
Publish Date	2015-03-12 19:39
Citation	Abdel-Salam OME. Drug therapy for Parkinson’s disease: An update. World J Pharmacol 2015; 4(1): 117-143
URL	http://www.wjgnet.com/2220-3192/full/v4/i1/117.htm
DOI	http://dx.doi.org/10.5497/wjp.v4.i1.117

Full Article (PDF)	WJP-4-117.pdf
Full Article (Word)	WJP-4-117.doc
Manuscript File	12108-Review.doc
Answering Reviewers	12108-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	12108-Conflict-of-interest statement.pdf
Copyright License Agreement	12108-Copyright assignment.pdf
Peer-review Report	12108-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	12108-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	12108-Scientific misconduct check.pdf
Scientific Editor Work List	12108-Scientific editor work list.pdf